On 25 February 2021, the CAT dismissed Lexon (UK) Limited’s (Lexon) appeal against a decision by the CMA finding an infringement under Chapter 1 of the Competition Act 1998. In March 2020, the CMA concluded an investigation into the supply of nortriptyline tablets in the UK between 2015 and 2017. The CMA found that Lexon, King Pharmaceuticals Ltd and Alissa Healthcare Research Ltd had entered into a concerted practice to inflate the price of nortriptyline tablets during this period. The CMA levied fines against all three companies and fined Lexon £1,220,383. Lexon subsequently appealed the CMA’s decision. The CAT found that Lexon had engaged in a concerted practice in relation to the supply of nortriptyline tablets. Lexon was found to have disclosed competitively sensitive information concerning prices and volumes. The CAT judgment also allows the CMA to continue director disqualification proceedings in the High Court against a former director of Lexon.